The anti-Her2 antibody, Herceptin, has proven effective in blocking the Her2 downstream signaling pathway [9], [10], [11] and in sensitizing Her2-expressing tumor cells to other treatments [12], [13]; however, there is no evidence that Herceptin alone induces potent tumor cell death. This evidence concerns the gene ERBB2 and neoplasm.